The scientific focus adapted
to express the optimum potential
of your molecule

Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News > 3rd Annual NASH Summit (April 22-25, 2019) in Boston, Massachusetts, USA.

News detail

Return to all news & events

04/17/2019 3rd Annual NASH Summit (April 22-25, 2019) in Boston, Massachusetts, USA.

Physiogenex will attend the 2019 edition of the NASH Annual Summit on April 23 and 24th in Boston.

The NASH Summit in Boston is one a leading industry forum for advancing the development of successful NASH therapeutics. This event is focused on discovery through to late-stage clinical development of non-alcoholic steatohepatitis (NASH) candidate pipelines. It brings together 300+ drug developers from 140+ organizations.

On Tuesday April the 23rd, Dr. François Briand, our Director of Research and Business Development, will present a poster dealing with our innovative NASH models and how they represent key assets for NASH treatments.

Poster #5 – The benchmarks Obeticholic Acid and Elafibranor show variable effects on NASH and hepatic fibrosis in diet-induced or chemically-induced animal models.

Dr. Briand will be happy to discuss with you about Physiogenex’s expertise on NASH and your need for rapid and efficient models.

Please Contact us to set-up an appointment.

About us

Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.

We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.